InvestorsHub Logo
Followers 14
Posts 3782
Boards Moderated 1
Alias Born 08/19/2015

Re: rayovacAAA post# 392109

Tuesday, 12/13/2022 12:16:06 PM

Tuesday, December 13, 2022 12:16:06 PM

Post# of 474310
Here is what Misleading said when Avatar result was released, similar statement after AD result.

https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints

[color=red]Based on the results in this Phase 3 study (ANAVEX®2-73-RS-002)[3] and the prior successful U.S. Phase 2 (ANAVEX®2-73-RS-001)[4] study in adult patients with Rett syndrome, Anavex is planning to meet with FDA to discuss the approval pathway. [/color]There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News